Asia
BeiGene’s Bruton’s kinase inhibitor Brukinsa (zanabrutinib) could be on its way for regulatory approval as a potential treatment for Waldenström’s macroglobulinemia (WM), a type of non-Hodgkin lymphoma.
Several mutations of the SARS-CoV-2 virus that causes COVID-19, which are being called variants, are increasingly being found around the world.
Pfizer’s COVID-19 vaccine data has once again been threatened by hackers. The alleged theft of intellectual property has been laid at the feet of North Korea’s government.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 16, 2021.
The origins of COVID-19 continue to be debated in the halls of government, and the findings from a recent investigation conducted by the World Health Organization are unlikely to change many minds as the world continues to grapple with the pandemic.
The cash just keeps coming for biopharma companies. Here’s a rundown of some of this week’s investment dollar recipients.
On the other hand, when dealing with a novel coronavirus, a certain amount of speed and urgency is necessary. Professor Chris Molloy, Chief Executive Officer of the U.K,’s Medicines Discovery Catapult, told BioSpace that real-time data should be considered, with a different lens applied.
A few companies shared some big Phase III results this week. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
Cross-continental drug development and commercialization deals are good for business, and imperative for patients to receive access to the most valuable scientific breakthroughs. This month has already brought a number of these partnerships for the treatment of cancer and other diseases. Here’s a look at three of them.
PRESS RELEASES